← Back to search
EITR BIOLOGICS, INC.
Doing business as EITR BIOLOGICS INC
SAN DIEGO, CA, 92121
UnclaimedClaim this profile (free)
Small Business
Prime contracting experience
9 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI | — | $33,059,642 | Jul 28, 2026 | Sep 22, 2023 – Sep 30, 2027 |
| Prime | Department of Defense Defense Health Agency | NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY | HT942523D0011USAspending | $269,999 | Mar 30, 2026 | Apr 1, 2026 – Mar 31, 2027 |
| Prime | Department of Defense Defense Health Agency | NOVEL BISPECIFIC BROAD SPECTRUM NANOBODY | HT942523D0011USAspending | $926,999 | Jan 28, 2026 | Feb 1, 2026 – Dec 31, 2027 |
| Prime | Department of Defense Defense Health Agency | NOVEL NANOTHERAPEUTICS | HT942523D0011USAspending | $1,864,156 | Jul 2, 2025 | Sep 20, 2024 – Dec 31, 2025 |
| Prime | Department of Defense Defense Health Agency | NOVEL NANOTHERAPEUTICS | HT942523D0011USAspending | $300,000 | May 19, 2025 | Jul 1, 2025 – Jun 30, 2026 |
| Prime | Department of Defense Defense Health Agency | SORTING PERIPHERAL BLOOD MONONUCLEAR CELLS FROM LASSA FEVER VIRUS SURVIVORS TO DISCOVER AND PRODUCE MONOCLONAL ANTIBODIES FOR ASSESSMENT IN IN VITRO AND IN VIVO ASSAYS | — | $729,721 | May 12, 2025 | Dec 6, 2023 – Dec 10, 2025 |
| Prime | Department of Defense Defense Health Agency | NOVEL CELL SORTING | — | $1,105,767 | Aug 28, 2024 | Nov 28, 2022 – Nov 27, 2024 |
| Prime | Department of Defense Defense Health Agency | DEVELOP A NOVEL ODIN THERAPEUTIC MEDICAL COUNTERMEASURE CAPABLE OF PROTECTING AGAINST PNEUMONIC UNENCAPSULATED Y. PESTIS. | HT942523D0011USAspending | $499,896 | May 16, 2024 | Jul 1, 2024 – Jun 30, 2025 |
| Prime | Department of Defense Defense Health Agency | NOVEL NANOTHERAPEUTIC APPROACHES PENETRATING THE OUTER LAYERS OF THE BACTERIUM AND TARGETING OUTER MEMBRANE PROTEINS FOR THE TREATMENT OF PNEUMONIC PLAGUE FOR ASSESSMENT IN IN VITRO AND IN VIVO ASSAYS | HT942523D0011USAspending | $750,000 | Aug 25, 2023 | Sep 1, 2023 – Aug 31, 2024 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
- Department of DefenseGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.